SCHEMBL5650255

SCHEMBL5650255

CCOC(=O)c1sc2c(ccc(=O)n2C(C)c2ccccc2)c1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.43
ALDH1A1 P00352 6/20 0.43
MAPT P10636 5/20 0.43
KDM4E B2RXH2 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HSD17B10 Q99714 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
GABRA1 P14867 2/20 0.41
GABRB2 P47870 2/20 0.41
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
LMNA P02545 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ABCB11 O95342 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650136 0.81 MAPT (0.51) HPGDALDH1A1MAPTKDM4ENPC1
SCHEMBL5648142 0.80 ALDH1A1 (0.42) HPGDALDH1A1MAPTKDM4ENPC1
SCHEMBL5651454 0.79 ALDH1A1 (0.54) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL5652293 0.78 MAPT (0.44) HPGDALDH1A1MAPTKDM4ENPC1
SCHEMBL5650867 0.78 MAPT (0.47) HPGDALDH1A1MAPTKDM4ENPC1
SCHEMBL5652764 0.77 MAPT (0.45) HPGDALDH1A1MAPTKDM4ENPC1
SCHEMBL5652595 0.77 MAPT (0.45) HPGDALDH1A1MAPTKDM4ENPC1
SCHEMBL5648783 0.77 LMNA (0.45) HPGDALDH1A1MAPTKDM4ENPC1
SCHEMBL5652931 0.77 ACACB (0.53) HPGDALDH1A1MAPTKDM4ENPC1
SCHEMBL5650265 0.76 PLAT (0.37) HPGDALDH1A1MAPTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 HPGD 1929/4885ALDH1A1 1498/4885MAPT 3795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.